All articles tagged with #vitt
Researchers traced vaccine-induced immune thrombocytopenia and thrombosis (VITT) to antibodies against PF4 caused by molecular mimicry with an adenovirus vector protein, enabling vaccine designers to modify the vector to remove the offending protein while maintaining protection.
An international study of 100 VITT patients shows the condition starts with antibodies that target an adenovirus protein; a single antibody mutation then makes them bind platelet factor 4 strongly, and a common immune gene variant shapes the response. VITT requires both a hereditary variant and a rare antibody mutation, explaining its rarity and offering clues for designing safer adenovirus-based vaccines in the future.
A global study of 100 VITT patients shows that the rare clotting after adenovirus-based vaccines arises when antibodies that initially target an adenoviral protein mutate once on a common immune gene background, enabling strong binding to platelet factor 4 and clot formation. This two-event trigger—inheritance of a specific immune gene variant and a rare mutation in antibody-producing cells after exposure—helps explain VITT’s rarity and could guide safer vaccine designs while preserving the value of adenovirus-based vaccines.
An international study explains the rare VITT clotting after certain adenoviral vaccines: a viral protein mimics PF4, and a somatic mutation in an antibody gene (K31E in IGLV3-21*02/*03) redirects antibodies to PF4, activating platelets. The mutation is essential and the condition is exceedingly rare because it requires both this mutation and a common antibody-gene variant (up to 60% of people). Reversing the mutation stops the clotting in experiments, offering a blueprint for safer adenoviral vaccines and insight into other antibody-driven adverse events.
A Nature study traces vaccine-induced immune thrombocytopenia and thrombosis (VITT) to a genetic mutation in antibody-producing cells that alters antibodies to bind PF4 after exposure to an adenovirus used in some COVID vaccines (AstraZeneca/J&J). This explains why rare clotting occurred in a subset of recipients and suggests a genetic predisposition, though not all carriers develop VITT; the researchers analyzed samples from 21 affected individuals and showed the mutated antibodies drive more clots in animal tests.